Generic Pharmasec Q4 FY26 Results: PAT Rs 5.45 Cr

Generic Pharmasec Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 5.45 crore for the quarter ended March 31, 2026, up 29.8% YoY compared to Rs 4.2 crore in Q4 FY25. Results are on a Standalone basis. Generic Pharmasec is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Generic Pharmasec Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Net Profit	5.45	4.2	+29.8%
Basis	Standalone

Note: FY26 net profit rose to Rs 5.45 crore (Rs 544.96 lakh). Generic pharmaceuticals manufacturer. Verify from BSE/NSE audited filings before investment decisions.

Generic Pharmasec Q4 FY26 Performance Analysis

The Generic Pharmasec Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. The company delivered results in line with its sector trends during the quarter. Generic Pharmasec operates in the Pharmaceuticals sector, benefiting from India’s GDP growth above 6.5% in FY26 and sustained domestic demand conditions.

The company’s profitability metrics reflect the key financial milestones for the Pharmaceuticals business in Q4 FY26.

Screen the best stocks on the Univest Screener.

Key Factors Driving Generic Pharmasec Q4 FY26 Results

Revenue and Operational Performance

Generic Pharmasec Q4 FY26 operational performance reflects the company’s business activities during the January to March 2026 quarter. The January to March period is the year-end quarter for Indian companies, characterised by strong execution cycles, project completions, and fiscal year-end activity.

Profitability Trends

The Generic Pharmasec Q4 FY26 PAT of Rs 5.45 crore up 29.8% YoY. Stable profitability reflects consistent operational delivery.

Sector and Macro Context

India’s macro environment in Q4 FY26 was supportive, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Pharmaceuticals sector saw broadly constructive demand conditions. For Generic Pharmasec, these macro tailwinds provided a supportive backdrop entering FY27.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin improvement trajectory, and capital allocation priorities will be the key investor watchpoints. The Pharmaceuticals sector continues to benefit from India’s structural growth drivers. Delivering consistent growth and margin expansion remains the strategic priority.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company